Department of oncology, Hospital Universitario Reina Sofia, Cordoba, Spain
Short Communication
Commentary on Efficacy and Safety of Trabectedin in Metastatic Uterine Leiomyosarcoma: A Retrospective Multicenter Study of the Spanish Ovarian
Cancer Research Group (GEICO)
Author(s): Maria Jesus Rubio*
Uterine Leiomyosarcoma (uLMS) is a very rare and aggressive carcinoma which, at advanced or recurrent stage, has a median overall survival of below 12 months. The Spanish ovarian cancer research group (GEICO), carried out a retrospective, observational, multicenter study involving 36 adult patients with unrespectable advanced or metastatic uLMS who received trabectedin after an anthracycline-containing regimen. The efficacy and safety observations found with trabectedin in this study were in line with previously shown in clinical trials.
Trabectedin provides long-term carcinoma stabilization and adequate tolerability, thus it represents an appropriate option for the treatment of advanced uLMS. Beneficial effects are optimized when administered as second-line, after the failure of the anthracycline-containing regimen, which allows achieving longer clinical benefit and disease.. View more»